Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.12 and traded as high as $3.38. Puma Biotechnology shares last traded at $3.35, with a volume of 323,078 shares trading hands.

Wall Street Analyst Weigh In

PBYI has been the topic of a number of research analyst reports. Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a report on Friday, February 28th.

Puma Biotechnology Stock Performance

The company has a market cap of $165.27 million, a PE ratio of 4.32 and a beta of 1.29. The firm's 50 day moving average is $3.26 and its 200-day moving average is $3.13. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53.

Insiders Place Their Bets

In related news, Director Adrian Senderowicz sold 27,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $3.40, for a total value of $91,800.00. Following the transaction, the director now directly owns 27,000 shares in the company, valued at approximately $91,800. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Brian M. Stuglik sold 8,100 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $3.39, for a total value of $27,459.00. Following the sale, the director now directly owns 94,958 shares of the company's stock, valued at approximately $321,907.62. This trade represents a 7.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 91,660 shares of company stock valued at $311,563 over the last ninety days. Company insiders own 23.30% of the company's stock.

Hedge Funds Weigh In On Puma Biotechnology

Several large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its position in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 6,351 shares during the last quarter. Graham Capital Management L.P. purchased a new position in Puma Biotechnology during the fourth quarter worth about $33,000. ProShare Advisors LLC acquired a new stake in shares of Puma Biotechnology during the fourth quarter valued at about $36,000. C2C Wealth Management LLC acquired a new stake in shares of Puma Biotechnology during the fourth quarter valued at about $37,000. Finally, Causeway Capital Management LLC purchased a new stake in shares of Puma Biotechnology in the 1st quarter valued at approximately $42,000. Institutional investors and hedge funds own 61.29% of the company's stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.